Announcement

Collapse
No announcement yet.

Reversing Aortic Stenosis?

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • Reversing Aortic Stenosis?

    Has anyone heard of a documented case of aortic stenosis being reversed? I know there are some anecdotal reports, but never any follow up to them. Dr Davis claimed he had 2 patients who had increased their aortic valve area by using vitamin K, but no follow up.

    This makes me think it was just an inaccurate echo-cardiogram reading, which is fairy common. I had the same thing with my valve area increasing dramatically between my 2nd and 3rd echo, after it had dramatically decreased between the 1st and 2nd echo. The 2nd echo had the area at severe level and the 1st and 3rd at moderate level.
    Last edited by rich; 01-28-2019, 06:46 PM.

  • #2
    Here are 2 old posts Dr Davis made in his blog at cureality about vitamin d and aortic stenosis. Again, he hasn't followed up recently, so this makes me think he doesn't have the data to back this up.

    http://www.cureality.com/blog/post/2...e-disease.html
    http://www.cureality.com/blog/post/2...vitamin-d.html

    And I found this current study:

    Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using 18F-Sodium Fluoride Positron Emission Tomography/Magnetic Resonance: The BASIK2 Rationale and Trial Design
    BASIK2 is a prospective, double-blind, randomized placebo-controlled trial investigating the effect of vitamin K2 (menaquinone-7;MK7) on imaging measurements of calcification in the bicuspid aortic valve (BAV) and calcific aortic valve stenosis (CAVS). BAV is associated with early development of CAVS. Pathophysiologic mechanisms are incompletely defined, and the only treatment available is valve replacement upon progression to severe symptomatic stenosis. Matrix Gla protein (MGP) inactivity is suggested to be involved in progression. Being a vitamin K dependent protein, supplementation with MK7 is a pharmacological option for activating MGP and intervening in the progression of CAVS. Forty-four subjects with BAV and mild–moderate CAVS will be included in the study, and baseline 18F-sodiumfluoride (18F-NaF) positron emission tomography (PET)/ magnetic resonance (MR) and computed tomography (CT) assessments will be performed. Thereafter, subjects will be randomized (1:1) to MK7 (360 mcg/day) or placebo. During an 18-month follow-up period, subjects will visit the hospital every 6 months, undergoing a second 18F-NaF PET/MR after 6 months and CT after 6 and 18 months. The primary endpoint is the change in PET/MR 18F-NaF uptake (6 months minus baseline) compared to this delta change in the placebo arm. The main secondary endpoints are changes in calcium score (CT), progression of the left ventricularremodeling response and CAVS severity (echocardiography). We will also examine the association between early calcification activity (PET) and later changes in calcium score (CT).

    Comment


    • #3
      Wow great info! Hope it's true.. I take a Vit. D/K2 supplement. I have Lpa so hoping it keeps my valves healthy.

      Comment

      Working...
      X